UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 29, 2013

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

DELAWARE

(State of Incorporation)

13-5315170

(I.R.S. Employer Identification No.)

235 East 42nd Street, New York, New York 10017

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

YES X

NO ___

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

YES X

NO ___

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act (check one):

Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

YES ____

NO X

At November 4, 2013, 6,481,070,845 shares of the issuer s voting common stock were outstanding.

Table of Contents

Table of Contents

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Income for the three and nine months ended September 29, 2013 and September 30, 2012

Condensed Consolidated Statements of Comprehensive Income for the three and nine months ended September 29, 2013 and September 30, 2012

Condensed Consolidated Balance Sheets as of September 29, 2013 and December 31, 2012

Condensed Consolidated Statements of Cash Flows for the nine months ended September 29, 2013 and September 30, 2012

Notes to Condensed Consolidated Financial Statements

Review Report of Independent Registered Public Accounting Firm

50

Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

51

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

98

Item 4.

Controls and Procedures

98

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

99

Item 1A.

Risk Factors

99

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

100

Item 3.

Defaults Upon Senior Securities

100

Item 4.

Mine Safety Disclosures

100

Item 5.

Other Information

100

Item 6.

Exhibits

101

Signature

102

Table of Contents

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(UNAUDITED)

Three Months Ended

Nine Months Ended

(MILLIONS, EXCEPT PER COMMON SHARE DATA)

September 29,

2013

September 30,

2012

September 29,

2013

September 30,

2012

Revenues

12,643

12,953

38,026

40,766

Costs and expenses:

Cost of sales(a)

2,287

2,309

6,792

7,068

Selling, informational and administrative expenses(a)

3,395

3,491

10,203

10,834

Research and development expenses(a)

1,627

1,887

4,867

5,461

Amortization of intangible assets

1,117

1,211

3,476

3,889

Restructuring charges and certain acquisition-related costs

233

312

547

1,085

Other (income)/deductions net

411

937

(514

3,264

Income from continuing operations before provision for taxes on income

3,573

2,806

12,655

9,165

Provision/(benefit) for taxes on income

985

(183

3,876

1,622

Income from continuing operations

2,588

2,989

8,779

7,543

Discontinued operations:

Income from discontinued operations net of tax

36

225

326

734

Gain on disposal of discontinued operations net of tax

(25

10,393

Discontinued operations net of tax

11

225

10,719

734

Net income before allocation to noncontrolling interests

2,599

3,214

19,498

8,277

Less: Net income attributable to noncontrolling interests

63

22

Net income attributable to Pfizer Inc.

2,590

3,208

19,435

8,255

Earnings per common share basic(b):

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.39

0.40

1.26

1.00

Discontinued operations net of tax

0.03

1.54

0.10

Net income attributable to Pfizer Inc. common shareholders

0.39

0.43

2.80

1.10

Earnings per common share diluted(b):

Income from continuing operations attributable to Pfizer Inc. common shareholders

0.39

0.40

1.25

1.00

Discontinued operations net of tax

0.03

1.52

0.10

Net income attributable to Pfizer Inc. common shareholders

0.39

0.43

2.77

1.09

Weighted-average shares basic

6,581

7,436

6,938

7,483

Weighted-average shares diluted

6,656

7,508

7,016

7,550

Cash dividends paid per common share

0.24

0.22

0.72

0.66

(a)

Excludes amortization of intangible assets, except as disclosed in Note 9B. Goodwill and Other Intangible Assets: Other Intangible Assets.

(b)

EPS amounts may not add due to rounding.

See Notes to Condensed Consolidated Financial Statements.

Table of Contents

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(UNAUDITED)

Three Months Ended

Nine Months Ended

(MILLIONS OF DOLLARS)

September 29,

2013

September 30,

2012

September 29,

2013

September 30,

2012

Net income before allocation to noncontrolling interests

2,599

3,214

19,498

8,277

Foreign currency translation adjustments

(21

153

(1,068

(1,565

Reclassification adjustments(a)

171

(21

153

(897

(1,565

Unrealized holding gains on derivative financial instruments

490

455

336

242

Reclassification adjustments for realized gains(b)

(313

(221

(64

(94

177

234

272

148

Unrealized holding gains/(losses) on available-for-sale securities

(156

26

(57

101

Reclassification adjustments for realized (gains)/losses(b)

(15

(9

(46

24

(171

17

(103

125

Benefit plans: actuarial gains/(losses), net

(13

(88

34

(592

Reclassification adjustments related to amortization(c)

137

122

438

351

Reclassification adjustments related to curtailments/settlements, net(c)

54

48

147

160

Foreign currency translation adjustments and other

(28

(37

112

18

150

45

731

(63

Benefit plans: prior service (costs)/credits and other

(3

23

Reclassification adjustments related to amortization(c)

(16

(20

(45

(54

Reclassification adjustments related to curtailments/settlements, net(c)

(4

(9

(86

Other

(4

(14

(22

(55

(116

Other comprehensive income/(loss), before tax

121

427

(52

(1,471

Tax provision on other comprehensive income/(loss)(d)

80

73

443

72

Other comprehensive income/(loss) before allocation to noncontrolling interests

41

354

(495

(1,543

Comprehensive income before allocation to noncontrolling interests

2,640

3,568

19,003

6,734

Less: Comprehensive income/(loss) attributable to noncontrolling interests

(32

(2

Comprehensive income attributable to Pfizer Inc.

2,672

3,563

19,005

6,731

(a)

Primarily reclassified into Gain on disposal of discontinued operations net of tax in the condensed consolidated statements of income.

(b)

Reclassified into Other (income)/deductions net in the condensed consolidated statements of income.

(c)

Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses, as appropriate, in the condensed consolidated statements of income. For additional information, see Note 10. Pension and Postretirement Benefit Plans.

(d)

See Note 5C. Tax Matters: Taxes on Items of Other Comprehensive Income/(Loss).

See Notes to Condensed Consolidated Financial Statements.

Table of Contents

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS OF DOLLARS)

September 29,

2013

December 31,

2012

(Unaudited)

Assets

Cash and cash equivalents

2,052

10,081

Short-term investments

31,627

22,318

Accounts receivable, less allowance for doubtful accounts

11,371

11,456

Inventories

6,482

6,076

Taxes and other current assets

7,835

8,956

Assets of discontinued operations and other assets held for sale

133

5,944

Total current assets

59,500

64,831

Long-term investments

15,731

14,149

Property, plant and equipment, less accumulated depreciation

12,359

13,213

Goodwill

42,400

43,661

Identifiable intangible assets, less accumulated amortization

40,549

45,146

Taxes and other noncurrent assets

4,982

4,798

Total assets

175,521

185,798

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt

4,738

6,424

Accounts payable

2,287

2,921

Dividends payable

1,733

Income taxes payable

802

979

Accrued compensation and related items

1,750

1,875

Other current liabilities

10,774

13,812

Liabilities of discontinued operations

21

1,442

Total current liabilities

20,373

29,186

Long-term debt

31,812

31,036

Pension benefit obligations

7,588

7,782

Postretirement benefit obligations

3,423

3,491

Noncurrent deferred tax liabilities

22,432

21,193

Other taxes payable

7,024

6,581

Other noncurrent liabilities

4,515

4,851

Total liabilities

97,167

104,120

Commitments and Contingencies

Preferred stock

35

39

Common stock

452

448

Additional paid-in capital

76,756

72,608

Treasury stock

(63,272

(40,122

Retained earnings

70,381

54,240

Accumulated other comprehensive loss

(6,383

(5,953

Total Pfizer Inc. shareholders equity

77,969

81,260

Equity attributable to noncontrolling interests

385

418

Total equity

78,354

81,678

Total liabilities and equity

175,521

185,798

See Notes to Condensed Consolidated Financial Statements.

Table of Contents

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Nine Months Ended

(MILLIONS OF DOLLARS)

September 29,

2013

September 30,

2012

Operating Activities

Net income before allocation to noncontrolling interests

19,498

8,277

Adjustments to reconcile net income before allocation to noncontrolling interests to net

cash provided by operating activities:

Depreciation and amortization

4,818

5,548

Share-based compensation expense

418

362

Gain associated with the transfer of certain product rights to an equity-method investment

(459

Asset write-offs and impairment charges

926

865

Gain on disposal of discontinued operations

(10,501

Deferred taxes from continuing operations

1,667

130

Deferred taxes from discontinued operations

(23

(10

Benefit plan expense in excess of contributions

258

86

Other non-cash adjustments, net

(311

(118

Other changes in assets and liabilities, net of acquisitions and divestitures

(4,312

(3,342

Net cash provided by operating activities

11,979

11,798

Investing Activities

Purchases of property, plant and equipment

(789

(833

Purchases of short-term investments

(33,927

(14,587

Proceeds from redemptions and sales of short-term investments

29,008

19,377

Net (purchases of)/proceeds from redemptions and sales of short-term investments with original maturities of 90 days or less

(2,177

1,483

Purchases of long-term investments

(8,746

(8,694

Proceeds from redemptions and sales of long-term investments

5,943

3,357

Acquisitions, net of cash acquired

(15

(782

Other investing activities

(2

(4

Net cash used in investing activities

(10,705

(683

Financing Activities

Proceeds from short-term borrowings

3,723

5,700

Principal payments on short-term borrowings

(3,776

(5,882

Net proceeds from/(payments on) short-term borrowings with original maturities of 90 days or less

1,831

(176

Proceeds from issuance of long-term debt(a)

6,618

Principal payments on long-term debt

(2,396

(14

Purchases of common stock

(11,643

(4,834

Cash dividends paid

(5,026

(4,915

Proceeds from exercise of stock options and other financing activities

1,438

355

Net cash used in financing activities

(9,231

(9,766

Effect of exchange-rate changes on cash and cash equivalents

(72

(25

Net increase/(decrease) in cash and cash equivalents

(8,029

1,324

Cash and cash equivalents, beginning

10,081

3,182

Cash and cash equivalents, end

2,052

4,506

Supplemental Cash Flow Information

Non-cash transactions:

Sale of Zoetis (our Animal Health business) for Pfizer common stock(b)

11,408

Exchange of Zoetis common stock for the retirement of Pfizer commercial paper issued in 2013(b)

2,479

Exchange of Zoetis senior notes for the retirement of Pfizer commercial paper issued in 2012(b)

992

Transfer of certain product rights to an equity-method investment(c)

1,233

Cash paid during the period for:

Income taxes

1,799

1,895

Interest

1,512

1,675

(a)

Includes $2.6 billion from the issuance of senior notes by Zoetis, our former Animal Health subsidiary, net of the non-cash exchange of Zoetis senior notes for the retirement of Pfizer commercial paper issued in 2012. See Note 2B. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investments: Divestitures.

(b)

See Note 2B. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investment: Divestitures.

(c)

See Note 2D. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investments: Equity-Method Investments.

See Notes to Condensed Consolidated Financial Statements.

Table of Contents

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation and Significant Accounting Policies

A. Basis of Presentation

We prepared the condensed consolidated financial statements following the requirements of the U.S. Securities and Exchange Commission (SEC) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by accounting principles generally accepted in the United States of America (U.S. GAAP) can be condensed or omitted.

Balance sheet amounts and operating results for subsidiaries operating outside the U.S. are as of and for the three and nine months ended August 25, 2013 and August 26, 2012.

On June 24, 2013, we completed the full disposition of our Animal Health business (Zoetis), and recognized a gain of approximately $10.4 billion, net of tax, related to the disposal of this business in Gain on disposal of discontinued operations net of tax in the condensed consolidated statements of income for the nine months ended September 29, 2013. The operating results of this business are reported as Income from discontinued operations net of tax in the condensed consolidated statements of income for the nine months ended September 29, 2013 and for the three and nine months ended September 30, 2012. In addition, in the condensed consolidated balance sheet as of December 31, 2012, the assets and liabilities associated with this business are classified as Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate. Prior period financial statements have been restated. For additional information, see Note 2B. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investments: Divestitures.

On November 30, 2012, we completed the sale of our Nutrition business to Nestl . The operating results of this business are reported as Income from discontinued operations net of tax in the condensed consolidated statements of income for the three and nine months ended September 30, 2012. For additional information, see Note 2B. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investments: Divestitures.

Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of our condensed consolidated balance sheets and condensed consolidated statements of income.

The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2012 Annual Report on Form 10-K/A.

B. Adoption of New Accounting Standards

There were no new accounting and disclosure standards adopted in the nine months ended September 29, 2013.

C. Fair Value

Our fair value methodologies depend on the following types of inputs:

Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).

Quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in markets that are not active or are directly or indirectly observable (Level 2 inputs).

Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).

A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.

Table of Contents

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 2. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investments

A. Acquisitions

NextWave Pharmaceuticals, Inc.

In the first quarter of 2013, we finalized the allocation of the consideration transferred to the assets acquired and the liabilities assumed in the acquisition of NextWave Pharmaceuticals Incorporated (NextWave), a privately held, specialty pharmaceutical company, completed on November 27, 2012. The total consideration for the acquisition was approximately $442 million, which consisted of upfront payments to NextWave's shareholders of approximately $278 million and contingent consideration with an estimated acquisition-date fair value of approximately $164 million. We recorded $519 million in Identifiable intangible assets, consisting of $474 million in Developed technology rights and $45 million in In-process research and development; $166 million in net deferred tax liabilities; and $89 million in Goodwill. In the third quarter and the first nine months of 2013, as a result of lowered commercial forecasts, the fair value of the contingent consideration decreased and we recognized a pre-tax gain of approximately $128 million and $109 million, respectively, in Other (income)/deductions net.

Alacer Corp.

On February 26, 2012, we completed our acquisition of Alacer Corp., a company that manufactures, markets and distributes Emergen-C, a line of effervescent, powdered drink mix vitamin supplements that is the largest-selling branded vitamin C line in the U.S. In connection with this Consumer Healthcare acquisition, we recorded $181 million in Identifiable intangible assets, consisting primarily of the Emergen-C indefinite-lived brand; $69 million in net deferred tax liabilities; and $192 million in Goodwill.

Ferrosan Holding A/S

On December 1, 2011, we completed our acquisition of the consumer healthcare business of Ferrosan Holding A/S (Ferrosan), a Danish company engaged in the sale of science-based consumer healthcare products, including dietary supplements and lifestyle products, primarily in the Nordic region and the emerging markets of Russia and Central and Eastern Europe. This acquisition is reflected in our condensed consolidated financial statements beginning in the first fiscal quarter of 2012. Our acquisition of Ferrosan s consumer healthcare business increases our presence in dietary supplements with a new set of brands and pipeline products. Also, we believe that the acquisition allows us to expand the marketing of Ferrosan s brands through Pfizer s global footprint and provide greater distribution and scale for certain Pfizer brands, such as Centrum and Caltrate, in Ferrosan s key markets. In connection with this Consumer Healthcare acquisition, we recorded $362 million in Identifiable intangible assets, consisting of indefinite-lived and finite-lived brands; $94 million in net deferred tax liabilities; and $322 million in Goodwill.

B. Divestitures

Animal Health Business Zoetis Inc.

On June 24, 2013, we completed the full disposition of our Animal Health business (Zoetis). The full disposition was completed through a series of steps, including the formation of Zoetis, an initial public offering (IPO) of an approximate 19.8% interest in Zoetis and an exchange offer for the remaining 80.2% interest.

Formation of Zoetis On January 28, 2013, our then wholly owned subsidiary, Zoetis, issued $3.65 billion aggregate principal amount of senior notes. Also, on January 28, 2013, we transferred to Zoetis substantially all of the assets and liabilities of our Animal Health business in exchange for all of the Class A and Class B common stock of Zoetis, $1.0 billion of the $3.65 billion of Zoetis senior notes, and an amount of cash equal to substantially all of the cash proceeds received by Zoetis from the remaining $2.65 billion of senior notes issued. The $1.0 billion of Zoetis senior notes received by Pfizer were exchanged by Pfizer for the retirement of Pfizer commercial paper issued in 2012, and the cash proceeds received by Pfizer of approximately $2.6 billion were used for dividends and stock buybacks.

Initial Public Offering (19.8% Interest) On February 6, 2013, an IPO of the Class A common stock of Zoetis was completed, pursuant to which we sold 99.015 million shares of Class A common stock of Zoetis (all of the Class A common stock, including shares sold pursuant to the underwriters' overallotment option to purchase additional shares, which was exercised in

Table of Contents

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

full) in exchange for the retirement of approximately $2.5 billion of Pfizer commercial paper issued in 2013. The Class A common stock sold in the IPO represented approximately 19.8% of the total outstanding Zoetis shares. The excess of the consideration received over the net book value of our divested interest was approximately $2.3 billion and was recorded in Additional paid-in capital. For additional information, see Note 6. Certain Changes in Total Equity.

Exchange Offer (80.2% Interest) On June 24, 2013, we exchanged all of our remaining interest in Zoetis, 400.985 million shares of Class A common stock of Zoetis (after converting all of our Class B common stock into Class A common stock, representing approximately 80.2% of the total outstanding Zoetis shares), for approximately 405.117 million outstanding shares of Pfizer common stock on a tax-free basis pursuant to an exchange offer made to Pfizer shareholders. The $11.4 billion of Pfizer common stock received in the exchange transaction was recorded in Treasury stock and was valued using the opening price of Pfizer common stock on June 24, 2013, the date we accepted the Zoetis shares for exchange. For additional information, see Note 6. Certain Changes in Total Equity. The gain on the sale of the remaining interest in Zoetis was approximately $10.4 billion, net of income taxes resulting from certain legal entity reorganizations, and was recorded in Gain on disposal of discontinued operations net of tax in the condensed consolidated statements of income for the nine months ended September 29, 2013.

In summary, as a result of the above transactions, we received approximately $6.1 billion of cash and Treasury stock valued at $11.4 billion.

The operating results of the animal health business are reported as Income from discontinued operations net of tax in the condensed consolidated statements of income for the nine months ended September 29, 2013 (through the disposal date) and for the three and nine months ended September 30, 2012. In addition, in the condensed consolidated balance sheet as of December 31, 2012, the assets and liabilities associated with this business are classified as Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations, as appropriate. Prior period financial statements have been restated.

In connection with the above transactions, we entered into a transitional services agreement (TSA) and manufacturing and supply agreements (MSAs) with Zoetis that are designed to facilitate the orderly transfer of business operations to the standalone Zoetis entity. The TSA relates primarily to administrative services, which are generally to be provided within 24 months. Under the MSAs, we will manufacture and supply certain animal health products to Zoetis for a transitional period of up to 5 years, with an ability to extend, if necessary, upon mutual agreement of both parties. These agreements are not material and none confers upon us the ability to influence the operating and/or financial policies of Zoetis subsequent to June 24, 2013, the full disposition date.

Nutrition Business

On November 30, 2012, we completed the sale of our Nutrition business to Nestl for $11.85 billion in cash, and recognized a gain of approximately $4.8 billion, net of tax. The divested business includes:

our former Nutrition operating segment and certain prenatal vitamins previously commercialized by the Pfizer Consumer Healthcare operating segment; and

other associated amounts, such as direct manufacturing costs, enabling support functions and other costs not charged to the business, purchase-accounting impacts, acquisition-related costs, impairment charges, restructuring charges and implementation costs associated with our cost-reduction/productivity initiatives, all of which are reported outside our operating segment results.

The operating results of this business are classified as Income from discontinued operations net of tax in the condensed consolidated statements of income for the three and nine months ended September 30, 2012.

Table of Contents

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Total Discontinued Operations

The following table provides the components of Discontinued operations net of tax:

Three Months Ended(a)

Nine Months Ended(a)

(MILLIONS OF DOLLARS)

September 29,

2013

September 30,

2012

September 29,

2013

September 30,

2012

Revenues

1,587

2,201

4,817

Pre-tax income from discontinued operations(a)

32

314

421

1,110

Provision for taxes on income(b)

(4

89

95

376

Income from discontinued operations net of tax

36

225

326

734

Pre-tax gain on disposal of discontinued operations

(38

10,501

Provision for taxes on income(c)

(13

108

Gain on disposal of discontinued operations net of tax

(25

10,393

Discontinued operations net of tax

11

225

10,719

734

(a)

Includes the Animal Health (Zoetis) business for the nine months ended September 29, 2013 (through the disposal date) and for the three and nine months ended September 30, 2012, and the Nutrition business for the three and nine months ended September 30, 2012. For the three months ended September 29, 2013, includes certain post-close adjustments.

(b)

Includes a deferred tax benefit of $4 million and $30 million for the three months ended September 29, 2013 and September 30, 2012, respectively, and a deferred tax benefit of $23 million and $10 million for the nine months ended September 29, 2013 and September 30, 2012, respectively. These deferred tax provisions include deferred taxes related to investments in certain foreign subsidiaries resulting from our intention not to hold these subsidiaries indefinitely.

(c)

For the nine months ended September 29, 2013, primarily reflects income taxes resulting from certain legal entity reorganizations.

The following table provides the components of Assets of discontinued operations and other assets held for sale and Liabilities of discontinued operations:

(MILLIONS OF DOLLARS)

September 29,

2013

December 31,

2012

Accounts receivable, less allowance for doubtful accounts

922

Inventories

1,137

Other current assets

550

Property, plant and equipment, less accumulated depreciation

133

1,318

Goodwill

1,011

Identifiable intangible assets, less accumulated amortization

867

Other noncurrent assets

139

Assets of discontinued operations and other assets held for sale

133

5,944

Current liabilities

21

874

Other liabilities

568

Liabilities of discontinued operations

21

1,442

The net cash flows of our discontinued operations for each of the categories of operating, investing and financing activities are not significant for the nine months ended September 29, 2013 and September 30, 2012.

C. Collaborative Arrangement

Collaboration for ertugliflozin

On April 29, 2013, we announced that we had entered into a worldwide, except Japan, collaboration agreement with Merck & Co., Inc. (Merck) for the development and commercialization of Pfizer's ertugliflozin (PF-04971729), an investigational oral sodium glucose cotransporter (SGLT2) inhibitor currently in Phase 3 development for the treatment of type 2 diabetes. Under the terms of the agreement, we will collaborate with Merck on the clinical development and commercialization of ertugliflozin,

10

Table of Contents

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

and ertugliflozin-containing fixed-dose combinations with metformin and Januvia (sitagliptin) tablets. Merck will continue to retain the rights to its existing portfolio of sitagliptin-containing products. Through September 29, 2013, we received payments totaling $60 million and we will be eligible for additional payments associated with the achievement of future clinical, regulatory and commercial milestones. The payments received to date have been deferred and are being recognized in Other (income)/deductions net over a multi-year period. We will share potential revenues and certain costs with Merck on a 60%/40% basis, with Pfizer having the 40% share. Each party has the right to terminate the agreement at certain times under certain circumstances, with various resulting rights and obligations depending on the nature of the termination.

D. Equity-Method Investments

Investment in ViiV Healthcare Limited

On August 12, 2013, the U.S. Food and Drug Administration (FDA) approved Tivicay (dolutegravir), a product for the treatment of HIV-1 infection, developed by ViiV Healthcare Limited (ViiV), an equity-method investee. This approval, in accordance with the agreement between GlaxoSmithKline plc and Pfizer, triggered a reduction in our interest in ViiV from 13.5% to 12.6% and an increase in GlaxoSmithKline plc's equity interest in ViiV from 76.5% to 77.4% effective October 1, 2013. As a result, in the third quarter of 2013, we recognized a loss of approximately $31 million in Other (income)/deductions net. We continue to account for our investment in ViiV under the equity method due to the significant influence that we continue to have through our board representation and minority veto rights.

Investment in Hisun Pfizer Pharmaceuticals Company Limited

On September 6, 2012, we and Zhejiang Hisun Pharmaceuticals Co., Ltd., a leading pharmaceutical company in China, formed a new company, Hisun Pfizer Pharmaceuticals Company Limited (Hisun Pfizer), to develop, manufacture, market and sell pharmaceutical products, primarily branded generic products, predominately in China. Hisun Pfizer was established with registered capital of $250 million, of which our portion was $122.5 million. On January 1, 2013, both parties transferred selected employees to Hisun Pfizer and contributed, among other things, certain rights to commercialized products and products in development, intellectual property rights, and facilities, equipment and distribution/customer contracts. Our contributions in 2013 constituted a business, as defined by U.S. GAAP, and included, among other things, the China rights to certain commercialized products and other products not yet commercialized and all associated intellectual property rights. As a result of the contributions from both parties, Hisun Pfizer holds a broad portfolio of branded generics covering cardiovascular disease, infectious disease, oncology, mental health, and other therapeutic areas. We hold a 49% equity interest in Hisun Pfizer.

We also entered into certain transition agreements designed to ensure and facilitate the orderly transfer of the business operations to Hisun Pfizer, primarily the Pfizer Products Transition Period Agreement and a related supply and promotional services agreement. These agreements provide for a profit margin on the manufacturing services provided by Pfizer to Hisun Pfizer and govern the supply, promotion and distribution of Pfizer products until Hisun Pfizer begins its own manufacturing and distribution. While intended to be transitional, these agreements may be extended by mutual agreement of the parties for several years and, possibly, indefinitely. These agreements are not material to Pfizer, and none confers upon us any additional ability to influence the operating and/or financial policies of Hisun Pfizer.

In connection with our contributions in the first quarter of 2013, we recognized a pre-tax gain of approximately $459 million in Other (income)/deductions net, reflecting the transfer of the business to Hisun Pfizer (including an allocation of goodwill from our Emerging Markets reporting unit as part of the carrying amount of the business transferred). Since we hold a 49% interest in Hisun Pfizer, we have an indirect retained interest in the contributed assets; as such, 49% of the gain, or $225 million, represents the portion of the gain associated with that indirect retained interest.

In valuing our investment in Hisun Pfizer (which includes the indirect retained interest in the contributed assets), we used discounted cash flow techniques, utilizing a 11.5% discount rate, reflecting our best estimate of the various risks inherent in the projected cash flows, and a nominal terminal year growth factor. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which include the expected impact of competitive, legal and/or regulatory forces on the products; the long-term growth rate, which seeks to project the sustainable growth rate over the long-term; and the discount rate, which seeks to reflect the various risks inherent in the projected cash flows, including country risk.

We are accounting for our interest in Hisun Pfizer as an equity-method investment, due to the significant influence we have over the operations of Hisun Pfizer through our board representation, minority veto rights and 49% voting interest. Our

11

Table of Contents

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

investment in Hisun Pfizer is reported as a private equity investment in Long-term investments, and our share of Hisun Pfizer's net income is recorded in Other (income)/deductions net. As of September 29, 2013, the carrying value of our investment in Hisun Pfizer is approximately $1.4 billion, and the amount of our underlying equity in the net assets of Hisun Pfizer is approximately $750 million. The excess of the carrying value of our investment over our underlying equity in the net assets of Hisun Pfizer has been allocated, within the investment account, to goodwill and other intangible assets. The amount allocated to other intangible assets is being amortized into Other (income)/deductions net over an average estimated useful life of 25 years.

Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives

We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example:

In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and

In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.

All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and research and development, as well as groups such as information technology, shared services and corporate operations. Since the acquisition of Wyeth on October 15, 2009, our cost-reduction initiatives announced on January 26, 2009, but not completed as of December 31, 2009, were incorporated into a comprehensive plan to integrate Wyeth s operations to generate cost savings and to capture synergies across the combined company. In addition, among our ongoing cost-reduction/productivity initiatives, on February 1, 2011, we announced a new productivity initiative to accelerate our strategies to improve innovation and productivity in R&D by prioritizing areas that we believe have the greatest scientific and commercial promise, utilizing appropriate risk/return profiles and focusing on areas with the highest potential to deliver value in the near term and over time.

12

Table of Contents